Dear @availlant, @ThomasTu,
Plz shed some light on this. Is this true?
2 Likes
Dear @Nawab
Yes it is true but it is pegIFN a2b. So no better performance than Pegasys (pegIFN a2a).
Its unfortunate that press releases are worded like this.
3 Likes
Dear @availlant,
How many months this extended Compassionate Access Program of Replicor 2139-Mg will last? On the Replicor website, it is written that the CA program is slated to deliver 36 courses. But i don’t know how many months these 36 courses of Replicor 2139-Mg will take.
-
Published studies of pegylated interferon α-2b (Pegbing / Peg-IFNα-2b) report substantially higher HBsAg-loss rates
-
Published studies of pegylated interferon α-2b (Pegbing / Peg-IFNα-2b) report substantially higher HBsAg-loss rates (often 40–65% in selected cohorts) than historical reports of interferon/NA therapy — especially in patients with low baseline HBsAg and when used as add-on therapy.
At 150 HBsAg
2 Likes
Could you point to some of these studies?
2 Likes
Wen et al., 2024 —
“Clinical cure induced by pegylated interferon α-2b…”
(largest cohort; 72-week follow-up)
2 Likes
I think this study:
They had very low HBsAg to begin with - many HBV drug regimens in clinical trial show substantial HBsAg loss with patients with low (below 100 IU/ml) levels of HBsAg.
Furthermore, the receiver operating characteristic curve showed baseline HBsAg< 72 IU/mL,
And if I’m not mistaken, the results don’t differ so much from standard pegylated interferon, as shown i.e. in this study:
The overall HBsAg clearance rate was 47%
Are you aware of any studies where participants were not chosen to have very low HBsAg levels?
2 Likes
Great analysis, @mantana!
TT
1 Like